CSIMarket Company Name, Ticker, Suppliers, else..
 
Y mabs Therapeutics inc   (NASDAQ: YMAB)
Other Ticker:  
 
 
Price: $4.1000 $-0.03 -0.726%
Day's High: $4.12 Week Perf: -8.99 %
Day's Low: $ 3.94 30 Day Perf: -19.45 %
Volume (M): 109 52 Wk High: $ 17.78
Volume (M$): $ 445 52 Wk Avg: $10.34
Open: $4.09 52 Wk Low: $3.84



 Market Capitalization (Millions $) 182
 Shares Outstanding (Millions) 44
 Employees 100
 Revenues (TTM) (Millions $) 88
 Net Income (TTM) (Millions $) -30
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0

Y Mabs Therapeutics Inc
Ymabs Therapeutics Inc. is a biopharmaceutical company that focuses on developing innovative antibody-based therapies for the treatment of cancer. The company specializes in the development of monoclonal antibodies that target specific tumor types and aims to improve patient outcomes by providing more effective and personalized treatment options. Ymabs Therapeutics takes a precision medicine approach, utilizing advanced technologies to identify and develop therapies that have the potential to selectively kill cancer cells while sparing healthy tissues. Its pipeline includes several promising drug candidates in various stages of development, with a focus on pediatric oncology. The company is committed to advancing medical science and making a meaningful impact in the lives of patients with cancer.


   Company Address: 202 Carnegie Center Princeton 8540 NJ
   Company Phone Number: 885-8505   Stock Exchange / Ticker: NASDAQ YMAB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -2.13%    
JNJ   -1.49%    
LLY        8.22% 
MRK        6.28% 
REGN        6.37% 
SNY        3.55% 
• View Complete Report
   



Management Announcement

Y-mAbs Therapeutics Implements Strategic Changes Amidst Financial Challenges

Published Fri, Jan 10 2025 12:05 PM UTC

Y-mAbs Therapeutics Inc. has recently made...
Clinical Study

Preclinical GD2-SADA Data to Revolutionize Cancer Treatment: A Comprehensive Analysis

Published Fri, Jun 7 2024 11:05 AM UTC

Y-mAbs Therapeutics, a pioneering biopharmaceutical company dedicated to advancing novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has recently unveiled groundbreaking preclinical data on GD2-SADA. This exciting revelation holds immense promise for the future of cancer treatment. The Society of Nuclear Medicine & Molecular Imaging (SNMM...
Clinical Study

Y-mAbs Reports Encouraging Interim Phase 2 Data for Naxitamab in High-Risk Neuroblastom...

Published Sat, Jun 1 2024 12:05 PM UTC

Y-mAbs Announces Promising Phase 2 Data for Naxitamab in the Treatment of High-Risk NeuroblastomaNEW YORK, June 01, 2024 - Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a leading biopharmaceutical company specializing in the development and commercialization of innovative radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has disclosed new interim d...
Y Mabs Therapeutics Inc

YMABsn Shatters Expectations with Massive Revenue Surge in Q3 2023



Y Mabs Therapeutics Inc, a major player in the pharmaceutical industry, recently released its fiscal year results for the period ending September 30, 2023. While the company showed improvements in some areas, it also experienced setbacks in others. This article will analyze the financial performance of Y Mabs Therapeutics Inc, highlighting interesting facts and providing insights for investors.
Revenue Growth and Loss:
Y Mabs Therapeutics Inc witnessed a notable increase in revenue, with a substantial 63.149% boost, from $12.54 million in the same reporting period last year to $20.45 million. However, the company experienced a sequential decrease in revenue of -1.431% from the previous quarter's $20.75 million.
Y Mabs Therapeutics Inc

Y Mabs Therapeutics Inc Reveals Puzzling Financial Behavior in Recent Quarter

Y Mabs Therapeutics Inc is a pharmaceutical company that specializes in developing novel cancer treatments. The company recently reported its financial results for the period of January to March 31, 2023, and it showed that the company had a net loss of $-0.15 per share. This is in comparison to a net loss of $-0.64 per share from the same period last year.
Despite the decrease in income per share, the revenue from the year rose significantly. The revenue grew by 93.124% to $20.25 million from $10.49 million in the corresponding quarter a year ago. However, sequentially, revenue tumbled by -35.603% from $31.45 million in the preceding quarter. This indicates that the company may be experiencing instability in its financials.






Y Mabs Therapeutics Inc's Segments
Product    100 % of total Revenue
Product Royalty Distribution agreement    6.14 % of total Revenue
United States Product    83.03 % of total Revenue
International Product    16.97 % of total Revenue
Eastern Asia Product    5.46 % of total Revenue
Latin America Product    6.89 % of total Revenue
Other regions Product    4.62 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com